Prime Medicine (PRME) Profit After Tax (2021 - 2026)

Prime Medicine (PRME) has 6 years of Profit After Tax data on file, last reported at -$49.1 million in Q1 2026.

• For the quarter ending Q1 2026, Profit After Tax rose 5.33% year-over-year to -$49.1 million; the trailing twelve-month figure through Mar 2026 stood at -$198.4 million (up 1.8% YoY), and the FY2025 full-year result was -$201.1 million, down 2.69% from the prior year.
• Profit After Tax for Q1 2026 stood at -$49.1 million, down from -$46.1 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$23.8 million in Q1 2022 and bottomed at -$65.6 million in Q4 2023.
• The 5-year median for Profit After Tax is -$46.1 million (2025), against an average of -$45.1 million.
• Peak annual rise in Profit After Tax reached 37.56% in 2022, while the deepest fall reached 78.83% in 2022.
• A 5-year view of Profit After Tax shows it stood at -$39.3 million in 2022, then sank by 67.1% to -$65.6 million in 2023, then jumped by 35.6% to -$42.3 million in 2024, then slipped by 9.0% to -$46.1 million in 2025, then dropped by 6.6% to -$49.1 million in 2026.
• The last three Profit After Tax figures came in at -$49.1 million (Q1 2026), -$46.1 million (Q4 2025), and -$50.6 million (Q3 2025), per Business Quant data.

Peer Comparison